



## Monogenic diabetes in children

**Aklima Afroze**

Department of Pharmacy, School of Pharmacy, China Pharmaceutical University, China

### Abstract

Monogenic forms of diabetes account for approximately 1–2% of diabetes in children and adolescents, and its incidence has increased in recent years due to greater awareness and wider availability of genetic testing. Monogenic diabetes is due to single gene defects that primarily affect beta cell function with more than 30 different genes reported. Children with antibody-negative, C-peptide-positive diabetes should be evaluated and genetically tested for monogenic diabetes. Accurate genetic diagnosis impacts treatment in the most common types of monogenic diabetes, including the use of sulfonylureas in place of insulin or other glucose-lowering agents or discontinuing pharmacologic treatment altogether.

**Keywords:** Monogenic diabetes, Maturity-onset diabetes of the young, Syndromic diabetes, Diagnostic evaluation, diabetes

### Introduction

Diabetes is characterized by hyperglycemia due to primary defects in insulin secretion and/or insulin action. The majority of diabetes can be classified as type 1 diabetes (T1D) or type 2 diabetes (T2D), both of which are complex, polygenic disorders. Monogenic forms of diabetes represent an uncommon heterogeneous group of single gene disorders primarily characterized by functional defects of pancreatic beta cells resulting in moderate to severe hyperglycemia<sup>[1, 2]</sup>. Monogenic forms of diabetes include neonatal diabetes mellitus, maturity-onset diabetes of the young (MODY), mitochondrial diabetes, and rare diabetes-associated syndromic diseases. There are now more than 30 genes found to be associated with different monogenic diabetes subtypes, many of which have provided considerable insight into molecular pathways relevant to beta cell physiology, insulin secretion, and action<sup>[3]</sup>. These gene discoveries have also led to significant improvements in patient care with several examples of personalized genomic medicine<sup>[4, 5]</sup>. This review will cover monogenic causes of pancreatic beta cell dysfunction presenting in childhood and adolescence, with a focus on clinical presentation, recognition, treatment, and management. We will begin by discussing the approach to diagnosing monogenic diabetes in children, followed by a review of the specific clinical characteristics and treatment of several forms of monogenic diabetes.

### Diabetes

Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy.

### Therapeutic implications of diagnosing monogenic diabetes in children

Earlier detection of monogenic diabetes in children and

Adolescents allows for personalized medicine. Treatment targeted to the genetic cause has been shown to result in improvements in glycemic control, fewer diabetes-related complications, and decreased cost and burden of treatment<sup>[20–23]</sup>. Studies have suggested that genetic testing for monogenic diabetes in appropriate populations is cost-effective<sup>[24, 25, 26, 27]</sup>. Distinguishing between monogenic diabetes and type 1 or type 2 diabetes also has important implications with regard to surveillance of complications and associated extra-pancreatic disorders and identification of affected and at-risk family members<sup>[28–30]</sup>.

### Approach to Genetic Diagnosis

Genetic testing should be done to confirm a clinical diagnosis of monogenic diabetes. As the number of genes associated with monogenic forms of diabetes increases, clinicians are left with a number of test options and approaches to diagnosis. Sanger sequencing remains the gold standard to detect single base substitutions and small insertions or deletions but limits the diagnosis to a few select genes, requiring a priori suspicion of the likely affected gene. Carroll *et al.* (2013) proposed a diagnostic algorithm where physicians first test the more common forms of Mody (*GCK*, *HNF1A*, and *HNF4A*) and only consider the rarer forms once those three were excluded<sup>[31]</sup>. Most commercial and clinical genetic laboratories have switched from Sanger sequencing to next-generation sequencing (NGS) approaches. Next-generation targeted sequencing panels allow for simultaneous analysis of all known diabetes-related genes in a single assay and are at a similar cost to testing a few genes by Sanger sequencing. More importantly, targeted panels may identify mutations in patients who do not present with the characteristic features of the disease<sup>[3]</sup>. One important consequence of using panels is that genetic testing results are more likely to include variants of uncertain significance. These variants are often difficult to interpret with regard to causality or disease risk and often require further patient medical information

and testing of first-degree relatives to assist in the analysis. Such circumstances pose a particular challenge for physicians when it comes to understanding and communicating results to patients and in making clinical management decisions. Requesting physicians should consult with experts in monogenic diabetes when causality of variants is uncertain.

### Prevalence of Monogenic Diabetes in Children

Several studies have systematically screened for monogenic diabetes or MODY in the pediatric population, with an estimated prevalence of 1.1–4.2% [6–10]. The SEARCH for Diabetes in Youth Study, a US multicenter population-based study, identified a minimum MODY prevalence of 1.2% and a further 0.2% with neonatal diabetes [9, 11]. A systematic population screening from UK pediatric clinics reported the prevalence of monogenic diabetes in cases diagnosed under the age of 20 years as 2.5% [10]. Recognition of Monogenic Diabetes in Children The term MODY was first used in the 1970s to describe heritable forms of diabetes distinct from insulin-dependent type 1 and noninsulin-dependent type 2 diabetes [12]. Now, MODY represents a clinically heterogeneous group of autosomal-dominant disorders caused by mutations in genes involved in beta cell development and insulin secretion and is the most common form of monogenic diabetes, estimated to account for 1–2% of diabetes cases (see Table 1) [13].

### Syndromic Diabetes

Syndromic forms of diabetes are rare, accounting less than 1% of children seen in diabetes clinics [92]. As they are rare and quite complex, most cases are either misdiagnosed or not diagnosed at all. The importance of correctly identifying such syndromes for children lies in the anticipation, recognition, and treatment of associated complications, and for the parents, the option of genetic counseling. Here, we discuss the most common syndromic forms that may be encountered in pediatric clinics. Additional syndromic forms and their underlying genetic cause can be found in Table 2.

### Maternally Inherited Diabetes and Deafness (MIDD)

Maternally inherited diabetes and deafness (MIDD) results from an A to G substitution at position 3243 (m.3243A>G) of the mitochondrial DNA encoding the gene for tRNA<sup>Leu</sup> and is estimated to affect up to 1% of patients with diabetes [93, 94]. Mitochondrial dysfunction in the highly metabolically active pancreatic islets is thought to result in gradual deterioration of beta cell function, loss of beta cell mass, and decreased glucose-induced insulin release [95, 96]. Other mitochondrial DNA point mutations have been associated with MIDD, but these are extremely rare compared with the proportion of diabetes caused by m.3243A>G [97].

### Clinical Features

The penetrance of diabetes in MIDD is high in carriers of the m.3243A>G mutation with a variable age of onset; the average age is 35 to 40 years with a range of 11 to 68 [94, 98]. The clinical picture of MIDD depends mainly on the amount of heteroplasmy in beta cells. Diabetes usually presents similarly to T2D, but approximately 20% present acutely, with ketoacidosis and, therefore, cases are misdiagnosed as T1D [98, 99]. Most do

not have islet cell or GAD antibodies; however, they have been detected in a small subset of patients [100, 101].

### Conclusion

Because monogenic diabetes is a genetically heterogeneous group of disorders, selection of appropriate gene(s) to test is challenging when based solely on clinical grounds. Pathogenic variants within several genes can present with similar phenotypic characteristics, while other features that are more gene specific may not yet have manifested at the time of initial presentation with hyperglycemia. Identification of monogenic forms of diabetes among children and adolescents remains a challenge, and as a result, these conditions are largely underdiagnosed with missed opportunities for genetically targeted management. Factors contributing to misdiagnosis include clinical and genetic heterogeneity of the different subtypes, clinical overlap with the more common polygenic forms of diabetes, high cost of commercial genetic testing, lack of insurance coverage, and limited knowledge of the condition by health care professionals. However, combining biomarkers with phenotype is a promising approach to lead to a more timely accurate genetic diagnosis.

### References

1. Flannick J, Johansson S, Njølstad PR Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. *Nat Publ Group*. 2016; 12(7):1-13. 10.1038/nrendo.2016.50. [PubMed] [CrossRef] [Google Scholar]
2. Vaxillaire M, Froguel P. Monogenic forms of diabetes mellitus: an update. *Endocrinol Nutr*. 2009; 56(S4):26-9. 10.1016/S1575-0922(09)73513-2. [PubMed] [CrossRef] [Google Scholar]
3. Alkorta-Aranburu G, Carmody D, Cheng YW, Nelakuditi V, Ma L, Dickens JT, *et al*. Phenotypic heterogeneity in monogenic diabetes: the clinical and diagnostic utility of a gene panel-based next-generation sequencing approach. *Mol Genet Metab*. 2014; 113(4):315-20. 10.1016/j.ymgme.2014.09.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. *Diabetologia*. 2017; 60(5):1-9. 10.1007/s00125-017-4226-2. Provides a review of the success of a precision medicine approach using monogenic forms of diabetes as an example. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Kleinberger JW, Pollin TI. Personalized medicine in diabetes mellitus: current opportunities and future prospects. *Ann N Y Acad Sci*. 2015; 1346(1):45-56. 10.1111/nyas.12757. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Ehtisham S, Hattersley AT, Dunger DB, Barrett TG, Group BSfPEaDCT. First UK survey of paediatric type 2 diabetes and MODY. *Arch Dis Child*. 2004; 89(6):526-9. 10.1136/adc.2003.027821. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Fendler W, Borowiec M, Baranowska-Jazwiecka A, Szadkowska A, Skala-Zamorowska E, Deja G, *et al*. Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign. *Diabetologia*. 2012; 55(10):2631-5. 10.1007/s00125-012-2621-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Irgens HU, Molnes J, Johansson BB, Ringdal M, Skriverhaug T, Undlien DE, *et al*. Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry. *Diabetologia*. 2013; 56(7):1512-9. 10.1007/s00125-013-2916-y. [PubMed] [CrossRef] [Google Scholar]

9. Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM, *et al.* Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. *J Clin Endocrinol Metab.* 2013; 98(10):4055-62. 10.1210/jc.2013-1279. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, *et al.* Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. *Diabetes Care.* 2016; 39(11):1879-88. 10.2337/dc16-0645. The study proposes the use of biomarkers in addition to clinical criteria as a useful approach to better identify cases of monogenic diabetes. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Kanakatti Shankar R, Pihoker C, Dolan LM, Standiford D, Badaru A, Dabelea D, *et al.* Permanent neonatal diabetes mellitus: prevalence and genetic diagnosis in the SEARCH for Diabetes in Youth Study. 2013; 14(3):174-80. 10.1111/pedi.12003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. *Diabetes.* 1975; 24(1):44-53. 10.2337/diabetes.24.1.44. [PubMed] [CrossRef] [Google Scholar]
13. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. *Diabetes Care.* 2011; 34(8):1878-84. 10.2337/dc11-0035. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
14. Bellané-Chantelot C, Lévy DJ, Carette C, Saint-Martin C, Riveline J-P, Larger E, *et al.* Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. *J Clin Endocrinol Metab.* 2011; 96(8):E1346-51. 10.1210/jc.2011-0268. [PubMed] [CrossRef] [Google Scholar]
15. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S, *et al.* Maturity-onset diabetes of the young (MODY): how many cases are we missing? *Diabetologia.* 2010; 53(12):2504-8. 10.1007/s00125-010-1799-4. [PubMed] [CrossRef] [Google Scholar]
16. Kleinberger JW, Copeland KC, Gandica RG, Haymond MW, Levitsky LL, Linder B, *et al.* Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. *Nat Publ Group.* 2017, 1-8. 10.1038/gim.2017.150. This study shows that a monogenic cause should be considered in children and adolescents with atypical diabetes regardless of BMI. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Harjutsalo V, Lammi N, Karvonen M, Groop P-H. Age at onset of type 1 diabetes in parents and recurrence risk in offspring. *Diabetes.* 2010; 59(1):210-4. 10.2337/db09-0344. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Warram JH, Krolewski AS, Gottlieb MS, Kahn CR. Differences in risk of insulin-dependent diabetes in offspring of diabetic mothers and diabetic fathers. *N Engl J Med.* 1984; 311(3):149-52. 10.1056/NEJM198407193110304. [PubMed] [CrossRef] [Google Scholar]
19. McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S, *et al.* High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. *Diabetes Care.* 2011; 34(8):1860-2. 10.2337/dc11-0323. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, *et al.* Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. *Diabet Med.* 2016; 33(7):976-84. 10.1111/dme.12992. [PubMed] [CrossRef] [Google Scholar]
21. Pearson ER, Liddell WG, Shepherd M, Corral RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. *Diabet Med.* 2000; 17(7):543-5. [PubMed] [Google Scholar]
22. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT, *et al.* No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. *Diabetes Care.* 2003; 26(11):3191-2. [PubMed] [Google Scholar]
23. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. *Diabet Med.* 2009; 26(4):437-41. 10.1111/j.1464-5491.2009.02690.x. [PubMed] [CrossRef] [Google Scholar]
24. Greeley SAW, John PM, Winn AN, Ornelas J, Lipton RB, Philipson LH, *et al.* The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. *Diabetes Care.* 2011; 34(3):622-7. 10.2337/dc10-1616. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Naylor RN, John PM, Winn AN, Carmody D, Greeley SAW, Philipson LH, *et al.* Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. *Diabetes Care.* 2014; 37(1):202-9. 10.2337/dc13-0410. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Nguyen HV, Finkelstein EA, Mital S, Gardner DS-L. Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. *J Med Genet.* 2017; 54(11):747-53. 10.1136/jmedgenet-2017-104670. This study provides another important example of the cost-effectiveness of genetic testing for MODY. [PubMed] [CrossRef] [Google Scholar]
27. Schnyder S, Mullis PE, Ellard S, Hattersley AT, Flück CE. Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment. *Swiss Med Wkly.* 2005; 135(23-24):352-6. [PubMed] [Google Scholar]
28. Kleinberger JW, Pollin TI. Undiagnosed MODY: Time for action. *Current Diabetes Reports.* 2015; 15(12):458-11. 10.1007/s11892-015-0681-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? *Clin Endocrinol.* 2011; 75(4):422-6. 10.1111/j.1365-2265.2011.04049.x. [PubMed] [CrossRef] [Google Scholar]
30. Shepherd M, Sparkes AC, Hattersley AT. Genetic testing in maturity onset diabetes of the young (MODY): a new challenge for the diabetic clinic. *Practical Diabetes International.* *Pract Diabetes Int.* 2001; 18(1):16-21. 10.1002/pdi.108. [CrossRef] [Google Scholar]
31. Carroll R, Murphy R. Monogenic diabetes: a diagnostic algorithm for clinicians. *Genes (Basel).* 2013; 4(4):522-35. 10.3390/genes4040522. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Vaxillaire M, Froguel P. Monogenic diabetes: implementation of translational genomic research towards precision medicine.

- Journal of Diabetes. 2016; 8(6):782-95. 10.1111/1753-0407.12446. [PubMed] [CrossRef] [Google Scholar]
33. McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. *Ann Clin Biochem.* 2013; 50(Pt5):403-15. 10.1177/0004563213483458. [PubMed] [CrossRef] [Google Scholar]
  34. Matschinsky FM. Regulation of pancreatic  $\beta$ -cell glucokinase: from basics to therapeutics. *Diabetes.* 2002; 51(suppl-3):S394-404. 10.2337/diabetes.51.2007.S394. [PubMed] [CrossRef] [Google Scholar]
  35. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njølstad PR, Hansen T, *et al.* The genetic abnormality in the beta cell determines the response to an oral glucose load. *Diabetologia.* 2002; 45(3):427-35. 10.1007/s00125-001-0770-9. [PubMed] [CrossRef] [Google Scholar]
  36. Steele AM, Wensley KJ, Ellard S, Murphy R, Shepherd M, Colclough K, *et al.* Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies. *PLoS One.* 2013; 8(6):e65326 10.1371/journal.pone.0065326. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  37. Spégel P, Ekholm E, Tuomi T, Groop L, Mulder H, Filipsson K, *et al.* Metabolite profiling reveals normal metabolic control in carriers of mutations in the glucokinase gene (MODY2). *Diabetes.* 2013; 62(2):653-61. 10.2337/db12-0827. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  38. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. *JAMA.* 2014; 311(3):279-86. 10.1001/jama.2013.283980. [PubMed] [CrossRef] [Google Scholar]
  39. Chakera AJ, Steele AM, Gloyn AL, Shepherd MH, Shields B, Ellard S, *et al.* Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. *Diabetes Care.* 2015; 38(7):1383-92. 10.2337/dc14-2769. [PubMed] [CrossRef] [Google Scholar]
  40. Dickens LT, Naylor RN. Clinical management of women with monogenic diabetes during pregnancy. *Curr Diab Rep.* 2018; 18(3):12 10.1007/s11892-018-0982-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  41. Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S, *et al.* Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. *Diabetologia.* 2014; 57(1):54-6. 10.1007/s00125-013-3075-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  42. Carmody D, Naylor RN, Bell CD, Berry S, Montgomery JT, Tadie EC, *et al.* GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated. *Acta Diabetol.* 2016; 53(5):703-8. 10.1007/s00592-016-0859-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  43. Wang H, Maechler P, Antinozzi PA, Hagenfeldt KA, Wollheim CB. Hepatocyte nuclear factor 4alpha regulates the expression of pancreatic beta -cell genes implicated in glucose metabolism and nutrient-induced insulin secretion. *J Biol Chem.* 2000; 275(46):35953-9. 10.1074/jbc.M006612200. [PubMed] [CrossRef] [Google Scholar]
  44. Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. *Proc Natl Acad Sci U S A.* 1997; 94(24):13209-14. [PMC free article] [PubMed] [Google Scholar]
  45. Colclough K, Bellanné-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. *Hum Mutat.* 2013; 34(5):669-85. 10.1002/humu.22279. [PubMed] [CrossRef] [Google Scholar]
  46. Pontoglio M, Priéd, Cheret C, Doyen A, Leroy C, Froguel P, *et al.* HNF1alpha controls renal glucose reabsorption in mouse and man. *EMBO Rep.* 2000; 1(4):359-65. 10.1093/embo-reports/kvd071. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
  47. Bellanné-Chantelot C, Carette C, Riveline J-P, Valéro R, Gautier J-F, Larger E, *et al.* The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. *Diabetes.* 2008; 57(2):503-8. 10.2337/db07-0859. [PubMed] [CrossRef] [Google Scholar]
  48. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ, *et al.* Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. *Nat Genet.* 2001; 27(4):375-82. 10.1038/86871. [PubMed] [CrossRef] [Google Scholar]
  49. Steele AM, Shields BM, Shepherd M, Ellard S, Hattersley AT, Pearson ER. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. *Diabet Med.* 2010; 27(2):157-61. 10.1111/j.1464-5491.2009.02913.x. [PubMed] [CrossRef] [Google Scholar]
  50. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gašperiková D, *et al.* A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. *Diabetologia.* 2011; 54(11):2801-10. 10.1007/s00125-011-2261-y. [PubMed] [CrossRef] [Google Scholar]